Contact Information: Contact: Zackary Irani 949-645-2111
Biomerica Board of Directors Adds New Member
| Source: Biomerica
NEWPORT BEACH, CA -- (MARKET WIRE) -- May 2, 2007 -- Biomerica, Inc. (OTCBB : BMRA ), a global
provider of advanced diagnostic products for the early detection of medical
conditions, today announced that its board of directors has increased the
size of the board from four to five members and elected Jane F. Emerson,
M.D., Ph.D., 52, Chief of Clinical Pathology and Vice-Chair for Clinical
Affairs, Department of Pathology and Laboratory Medicine University of
California, Irvine, to the board.
"Dr. Emerson's understanding and foresight in the diagnostics' market is
very impressive," said Biomerica chairman Zack Irani. "With her rich
entrepreneurial, clinical and medical background, she will be a tremendous
addition to our board."
"There are very few companies the size of Biomerica that have the potential
to make an impact in consumer healthcare," Dr. Emerson said. "I look
forward to working with Biomerica as a board member to help shape the
direction of the company as it continues to grow."
Dr. Emerson has received numerous honors, including an NIH Fellowship in
Mechanisms of Insulin Action; grants including Investigator for Alzheimer's
Disease Research Center, NIH; and has been a reviewer in journals including
the Journal of Cancer Prevention and Detection. Dr. Emerson is the author
of 4 patents and has presented or published over 28 articles/papers in the
diagnostic field.
About Biomerica (OTCBB : BMRA )
Biomerica, Inc. (www.biomerica.com) is a global medical technology company
based in Newport Beach, CA. The Company manufactures and markets advanced
diagnostic products used at home, in hospitals, and in physicians' offices
for the early detection of medical conditions and diseases.
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements. Certain information included in
this press release (as well as information included in oral statements or
other written statements made or to be made by Biomerica) contains
statements that are forward looking; such as statements relating to
intended launch dates, sales potential, significant benefits, market size,
growth of business, favorable positions, expansion, expected orders,
leading market positions, anticipated future revenues or production volume
of the Company, success of product and new product offerings.
Such forward-looking information involves important risks and uncertainties
that could significantly affect anticipated results in the future, and
accordingly, such results may differ materially from those expressed in any
forward-looking statements made by or on behalf of Biomerica. The potential
risks and uncertainties include, among others, fluctuations in the
Company's operating results due to its business model and expansion plans,
downturns in international and or national economies, the Company's ability
to raise additional capital, the competitive environment in which the
Company will be competing, and the Company's dependence on strategic
relationships. The Company is under no obligation to update any
forward-looking statements after the date of this release.